

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Hepatology*

**Manuscript NO:** 70598

**Title:** Efficacy and Safety of Sofosbuvir/Velpatasvir with or without ribavirin in Hepatitis C Genotype 3 compensated cirrhosis: A meta-analysis

**Provenance and peer review:** Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 01807964

**Position:** Editorial Board

**Academic degree:** MD

**Professional title:** Professor

**Reviewer's Country/Territory:** Austria

**Author's Country/Territory:** Singapore

**Manuscript submission date:** 2021-08-08

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-08-30 07:21

**Reviewer performed review:** 2021-08-31 07:54

**Review time:** 1 Day

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="checkbox"/> ] Anonymous [ <input type="checkbox"/> ] Onymous Conflicts-of-Interest: [ <input checked="" type="checkbox"/> ] Yes [ <input type="checkbox"/> ] No
-------------------------------------	---

#### **SPECIFIC COMMENTS TO AUTHORS**

This metaanalysis confirms as expected the results of the icluded studies. The manuscript is well written ans the statisical evaluation is robust. The message is not really new and 8 years after DAA became available the readership interested in such a metaanalysis may be quite small

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Hepatology*

**Manuscript NO:** 70598

**Title:** Efficacy and Safety of Sofosbuvir/Velpatasvir with or without ribavirin in Hepatitis C Genotype 3 compensated cirrhosis: A meta-analysis

**Provenance and peer review:** Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 00030389

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Director

**Reviewer's Country/Territory:** Japan

**Author's Country/Territory:** Singapore

**Manuscript submission date:** 2021-08-08

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-09-06 03:00

**Reviewer performed review:** 2021-09-10 01:43

**Review time:** 3 Days and 22 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

**Peer-reviewer  
statements**

Peer-Review: [☒] Anonymous [☐] Onymous

Conflicts-of-Interest: [☐] Yes [☒] No

#### **SPECIFIC COMMENTS TO AUTHORS**

The authors evaluated the efficacy and safety of SOF/VEL, with or without RBV in GT3 compensated cirrhosis patients by meta-analysis. They found that RBV was not associated with higher SVR12 in GT3 compensated cirrhosis patients receiving SOF/VEL. The manuscript is interesting. I have only a few comments. Major comments #1. Abstract, Results, and Discussion. "Subgroup analysis showed that ribavirin was associated with a higher SVR12 in GT3 compensated cirrhosis patients with baseline resistance-associated substitutions (RAS)." The authors should mention that most of the patients assessed for RAS were from the report from Esteban and there was no statistical significance. They should mention these in Discussion as the limitation. Minor comments #1. P6, line 23. "Ribavirin" should be "ribavirin (RBV)", since this is the 1st appearance. After this, RBV should be used .

## RE-REVIEW REPORT OF REVISED MANUSCRIPT

**Name of journal:** *World Journal of Hepatology*

**Manuscript NO:** 70598

**Title:** Efficacy and Safety of Sofosbuvir/Velpatasvir with or without ribavirin in Hepatitis C Genotype 3 compensated cirrhosis: A meta-analysis

**Provenance and peer review:** Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 00030389

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Director

**Reviewer's Country/Territory:** Japan

**Author's Country/Territory:** Singapore

**Manuscript submission date:** 2021-08-08

**Reviewer chosen by:** Han Zhang (Online Science Editor)

**Reviewer accepted review:** 2022-01-21 11:22

**Reviewer performed review:** 2022-01-22 00:31

**Review time:** 13 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Peer-reviewer</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

statements

Conflicts-of-Interest: [ ] Yes [Y] No

## **SPECIFIC COMMENTS TO AUTHORS**

In the revised version of their manuscript, the authors have properly answered to the points raised by the reviewer. Minor comment #1. P7, line 8. “sustained virologic response 12 wk post-treatment (SVR12)”. This is the 2nd or later appearance of SVR, and there is no need to spell it out.